Enveric Biosciences, Inc. (ENVB) - Dilution Analysis

10-Q filing | 3.7M shares outstanding

10-K filing | 1.9M shares outstanding

S-3 filing: The selling stockholders are offering on a resale basis an aggregate of 882,627 shares of common stock issuable upon the exercise of warrants.

8-K filing: Enveric Biosciences, Inc. entered into warrant exercise inducement offer letters with certain institutional investors, resulting in the exercise of existing warrants and the issuance of new warrants, with gross proceeds of approximately $3.1 million. ($3.15M proceeds)

S-3/A filing: The Selling Stockholders identified in this prospectus are offering on a resale basis an aggregate of 418,313 shares of Common Stock issuable upon the exercise of the Warrants.

10-Q filing | 0.6M shares outstanding

8-K filing: Enveric Biosciences, Inc. entered into warrant exercise inducement offer letters with certain institutional investors, leading to the exercise of existing warrants and issuance of new warrants for gross proceeds of approximately $2.2 million. ($2.2M proceeds)

10-Q filing | 2.5M shares outstanding

S-3/A filing: Enveric Biosciences, Inc. is offering common stock with an aggregate offering price of up to $1,854,151 through an at-the-market offering agreement with H.C. Wainwright & Co.

10-K filing | 2.5M shares outstanding

8-K filing: Enveric Biosciences, Inc. closed a public offering of 1,229,330 shares of common stock, 437,336 pre-funded warrants, 1,666,666 Series A warrants, and 1,666,666 Series B warrants on February 3, 2025, with net proceeds of approximately $4.3 million.

S-1/A filing: Enveric Biosciences, Inc. is offering up to 1,204,819 shares of common stock, together with Series A warrants to purchase up to 1,204,819 shares of common stock, Series B warrants to purchase up to 1,204,819 shares of common stock, and up to 1,204,819 pre-funded warrants to purchase up to 1,204,819 shares of common stock.

S-1/A filing: The company will issue warrants to Wainwright or its designees to purchase common stock. The number of shares will equal 7.0% of the aggregate number of shares of common stock placed in each offering.

S-1 filing: Enveric Biosciences, Inc. is offering shares of common stock and warrants.

10-Q filing | 9.9M shares outstanding

S-1 filing: This prospectus relates to the offer and resale of up to 4,900,000 shares of our common stock by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder.

10-Q filing | 8.9M shares outstanding

S-3 filing: The company may offer and sell common stock, preferred stock, warrants and/or units, up to an aggregate amount of $200.0 million.

10-Q filing | 7.8M shares outstanding

8-K filing: Enveric Biosciences, Inc. entered into purchase agreements for a registered direct offering of 458,000 shares of common stock at a deemed offering price of $0.94 per share, in exchange for a waiver of a variable rate transaction limitation.

10-K filing | 7.3M shares outstanding

8-K filing: Enveric Biosciences, Inc. entered into a series of common stock purchase agreements for the issuance of 228,690 shares of common stock to certain institutional investors in exchange for the waiver of a variable rate transaction limitation related to an "at the market" offering.

S-3 filing: This S-3 filing registers 2,244,000 shares of Enveric Biosciences, Inc. common stock for resale by selling stockholders, including shares issuable upon exercise of warrants from a private placement that closed on December 28, 2023.

8-K filing: Enveric Biosciences, Inc. entered into warrant exercise inducement offer letters with certain holders of existing warrants, who agreed to exercise their warrants to purchase 1,122,000 shares of the Company's common stock at a reduced price of $1.37 per share, in exchange for new warrants to purchase up to 2,244,000 shares and a cash payment of $0.125 per Inducement Warrant Share. ($1.8M proceeds)

S-1/A filing: This prospectus relates to the offer and resale of up to 1,279,880 shares of our common stock, par value $0.01 per share, by Lincoln Park Capital Fund, LLC.

10-Q filing | 2.2M shares outstanding

S-1 filing: This prospectus relates to the offer and resale of up to 1,279,880 shares of our common stock, par value $0.01 per share, by Lincoln Park Capital Fund, LLC.

8-K filing: Enveric Biosciences, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, for the sale of up to $10.0 million of the Company's common stock, and issued 139,403 commitment shares to Lincoln Park as consideration for its commitment to purchase shares of Common Stock under the Purchase Agreement.

10-Q filing | 2.1M shares outstanding

10-Q filing | 2.1M shares outstanding

10-K filing | 2.1M shares outstanding

10-Q filing | 2.1M shares outstanding

10-Q filing | 1.6M shares outstanding

S-3 filing: This S-3 filing relates to the resale by selling stockholders of up to 1,695,000 shares of common stock.

8-K filing: Enveric Biosciences, Inc. completed a registered direct offering and a private placement, selling shares of common stock, pre-funded warrants, and preferred investment options, resulting in gross proceeds of $3,000,000 and $5,000,000 respectively. ($24.0M proceeds)

10-Q filing | 52.7M shares outstanding

8-K filing: Acanna Therapeutics, Inc., a wholly-owned subsidiary of Enveric Biosciences, Inc., entered into a Securities Purchase Agreement to sell up to 5,000 shares of Series A Convertible Preferred Stock at $1,000 per share and warrants for up to $5,000,000 in a private placement, with 1,000 shares issued for $1,000,000 on May 5, 2022, and the remainder to be issued upon completion of the spin-off. ($1.0M proceeds)

10-K filing | 52.6M shares outstanding

8-K filing: Enveric Biosciences, Inc. completed a firm commitment offering of 20,000,000 shares of common stock and accompanying warrants, and the underwriter exercised its option to purchase warrants for an additional 3,000,000 shares, with net proceeds of approximately $9.2 million. ($10.0M proceeds)

8-K filing: Enveric Biosciences issued 1,194,843 shares of common stock in exchange for warrants to purchase 698,517 shares, and completed the amalgamation of MagicMed Industries Inc.

10-Q filing | 31.4M shares outstanding

10-Q filing | 21.4M shares outstanding

S-3 filing: Enveric Biosciences files an S-3 to offer common stock and preferred stock, among other securities, up to an aggregate amount of $200.0 million.

10-Q filing | 21.4M shares outstanding

S-3/A filing: Registration of shares of common stock and shares of common stock issuable upon exercise of warrants held by selling stockholders.

10-K filing | 5.8M shares outstanding

S-3 filing: This is an S-3 filing for the offering of up to 5,497,878 shares of common stock by selling stockholders, including shares that may be issued upon exercise of warrants.

8-K filing: Enveric Biosciences, Inc. entered into a Securities Purchase Agreement to issue and sell 3,007,026 shares of common stock at $4.27 per share in a registered direct offering, for gross proceeds of approximately $12,840,000. ($12.84M proceeds)

8-K filing: Enveric Biosciences, Inc. entered into a Securities Purchase Agreement to issue and sell 2,221,334 shares of common stock at $4.5018 per share in a registered direct offering, for gross proceeds of approximately $10,000,000, and will issue warrants to purchase up to 1,666,019 shares of common stock. ($10.0M proceeds)

8-K filing: The company issued Series B Warrants to Alpha Capital Anstalt to purchase 1,791,923 shares of common stock at an exercise price of $0.01 and all outstanding shares of Series A Preferred Stock were redeemed for an equal number of shares of Private Ameri Preferred Stock and the company announced a Reverse Stock Split.

8-K filing: Ameri and Jay Pharma amended their Tender Agreement, revising the Exchange Ratio due to Ameri note conversions and Alpha's investment in Jay Pharma, which impacts the number of shares to be issued in the merger. ($0.3M proceeds)

10-Q filing | 5.7M shares outstanding

10-Q filing | 5.2M shares outstanding

8-K filing: Ameri Holdings, Inc. entered into a securities purchase agreement for the issuance of 373,766 shares of common stock, pre-funded warrants to purchase up to 150,000 shares of common stock, and warrants to purchase up to 340,448 shares of common stock for an aggregate purchase price of $1,000,000 in a registered direct offering and concurrent private placement. ($1.0M proceeds)

8-K filing: Ameri Holdings, Inc. completed a registered direct offering of 862,500 shares of common stock at $2.00 per share, resulting in gross proceeds of approximately $1.725 million, and issued warrants to the placement agent to purchase up to 60,375 shares of common stock at an exercise price of $2.20 per share. Additionally, the company exchanged convertible notes for a new convertible debenture convertible into shares of common stock at a conversion price of $1.75 per share. ($1.73M proceeds)

8-K filing: Ameri Holdings, Inc. entered into an Amalgamation Amendment Agreement on May 26, 2020, to amend the Amalgamation Agreement dated January 10, 2020, revising terms related to the issuance of ExchangeCo Special Shares and other considerations in the merger with Jay Pharma Inc.

10-Q filing | 3.2M shares outstanding

8-K filing: Ameri Holdings, Inc. entered into a Maturity Extension and Forbearance Agreement with the holder of its convertible promissory notes, issuing a warrant to purchase up to 646,094 shares of common stock at $0.001 per share. They also entered into an Amalgamation Amendment Agreement which will issue series B warrants to acquire 8,100,000 shares of common stock of the company resulting from the amalgamation.

10-K filing | 3.2M shares outstanding

8-K filing: Ameri Holdings, Inc. entered into a Stock Purchase Agreement to sell Ameri100 Holdco, Inc., issued 599,600 shares of common stock in exchange for debt, and entered into an Amalgamation Agreement with Jay Pharma Inc. ($1.5M proceeds)